MDT.N Hits 52-Week High on Strong Q2 Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2026
0mins
Source: CNBC
Shares of Medtronic plc (MDT.N) surged to a 52-week high following the company's impressive Q2 FY26 earnings report, which revealed a revenue increase of 6.6% to $9.0 billion and a GAAP diluted EPS rise of 8% to $1.07, surpassing analyst expectations. The stock's breakout was fueled by robust performance in the Cardiac Ablation Solutions segment, which saw a remarkable 71% revenue growth, particularly driven by the pulsed field ablation portfolio. Additionally, Medtronic raised its FY26 revenue growth guidance to approximately 5.5%, reflecting strong confidence in ongoing growth and market expansion, particularly with new product approvals enhancing its portfolio. Despite the positive outlook, some analysts express concerns over potential overvaluation in the current market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDT
Wall Street analysts forecast MDT stock price to rise
20 Analyst Rating
11 Buy
9 Hold
0 Sell
Moderate Buy
Current: 78.140
Low
102.00
Averages
111.76
High
120.00
Current: 78.140
Low
102.00
Averages
111.76
High
120.00
About MDT
Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Dividend Stocks as a Risk Reduction Strategy
- Stability in Healthcare: Medtronic, a leader in the medical device industry, shows an 8% revenue growth in its latest fiscal year, and with a dividend yield of 3.6% and a low P/E ratio of 13, it presents an attractive investment opportunity amid market volatility.
- REIT Advantages: Realty Income achieved a 9% revenue growth to $5.7 billion in 2025, and its diverse tenant mix reduces risk, making it appealing for risk-averse investors with the highest dividend yield of 5.2% on this list.
- Energy Stock Resilience: ExxonMobil, a giant in the oil and gas sector, has a dividend yield of 2.9% and saw its stock surge 26% over the past year, demonstrating its stability as it rose 80% when the S&P 500 fell by 19% in 2022, showcasing its risk mitigation capabilities.
- Portfolio Diversification: Investing in these low-volatility stocks allows investors to effectively reduce exposure to market fluctuations, particularly in the context of rising valuations, thereby enhancing the resilience of their investment portfolios.
See More
Recommended Dividend Stocks for Stable Income
- Healthcare Industry Leader: Medtronic, a leading medical device manufacturer, benefits from ongoing product demand, with its latest fiscal year showing an 8% revenue growth, indicating stable growth trends, while its dividend yield stands at 3.6%, significantly higher than the S&P 500's 1.1%.
- Advantages of REITs: Realty Income achieved a 9% revenue growth in 2025, reaching $5.7 billion, and by maintaining a diverse tenant mix, it mitigates risk, offering a dividend yield of 5.2% and consistently increasing dividends, which boosts investor confidence.
- Stability of Oil Giants: ExxonMobil, known for its 2.9% dividend yield and a beta of just 0.15, indicates low sensitivity to market fluctuations, with a 26% stock price increase over the past year, showcasing its resilience during market downturns, making it an ideal choice for portfolio diversification.
- Risk Management in Portfolios: Amid increasing market volatility, investing in these low-volatility dividend stocks not only reduces investment risk but also provides stable cash flow, making them suitable for risk-averse investors seeking long-term returns.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Challenges
- Increased Stake: Citadel Advisors raised its stake in Intuitive Surgical by 30.3% in Q1, demonstrating confidence in the company's long-term growth potential despite facing challenges such as increased competition and tariffs.
- Market Competition: Intuitive Surgical is encountering competitive pressure in the robotic-assisted surgery market from companies like Medtronic and Johnson & Johnson; however, its 26 years of market experience and strong customer base help maintain its leading position.
- Financial Pressures: Despite relatively strong financial results, Intuitive Surgical's stock has dropped 20% over the past 12 months due to declining product margins and tariff impacts, raising investor concerns about its future performance.
- Long-Term Outlook: Intuitive Surgical is exploring ways to leverage artificial intelligence to enhance its device capabilities, and despite current challenges, its vast market potential and high switching costs provide a solid foundation for future growth.
See More
Three Dividend Stocks Worth Investing In
- Bristol Myers Squibb's Growth Potential: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, with new drug sales increasing 12% to $6.2 billion, indicating a strong recovery in its oncology portfolio that could further enhance sales growth in the future.
- Merck's Product Diversification: Despite competitive pressures, Merck's newer products have an annual revenue exceeding $1 billion, with the pulmonary arterial hypertension drug Winrevair generating $525 million in Q1, an impressive 88% year-over-year increase, showcasing the company's strong performance in new markets.
- Medtronic's Strategic Restructuring: Medtronic announced the spin-off of its diabetes care division into a standalone public company to enhance overall operational efficiency, while its new Pulse Field Ablation devices are positively impacting revenue growth in recent quarters.
- Attractive Dividend Yields: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, all of which have significantly increased their dividends over the past decade, demonstrating a strong commitment to shareholder returns.
See More
IYH ETF 52-Week Price Range Analysis
- Price Range Analysis: The IYH ETF has a 52-week low of $53.935 and a high of $67.63, with the latest trade at $62.63, indicating relative stability in the ETF's market position, which may attract investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average can provide valuable insights for investors, helping them assess market trends and potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify ETFs experiencing notable inflows (new units created) or outflows (old units destroyed), allowing for an assessment of their impact on underlying assets and market dynamics.
See More
Dividend Stocks as a Risk Reduction Strategy
- Stability in Healthcare: Medtronic, a leader in the medical device industry, shows an 8% revenue growth in its latest fiscal year, and with a dividend yield of 3.6% and a low P/E ratio of 13, it presents an attractive investment opportunity amid market volatility.
- REIT Advantages: Realty Income achieved a 9% revenue growth to $5.7 billion in 2025, and its diverse tenant mix reduces risk, making it appealing for risk-averse investors with the highest dividend yield of 5.2% on this list.
- Energy Stock Resilience: ExxonMobil, a giant in the oil and gas sector, has a dividend yield of 2.9% and saw its stock surge 26% over the past year, demonstrating its stability as it rose 80% when the S&P 500 fell by 19% in 2022, showcasing its risk mitigation capabilities.
- Portfolio Diversification: Investing in these low-volatility stocks allows investors to effectively reduce exposure to market fluctuations, particularly in the context of rising valuations, thereby enhancing the resilience of their investment portfolios.
See More
Recommended Dividend Stocks for Stable Income
- Healthcare Industry Leader: Medtronic, a leading medical device manufacturer, benefits from ongoing product demand, with its latest fiscal year showing an 8% revenue growth, indicating stable growth trends, while its dividend yield stands at 3.6%, significantly higher than the S&P 500's 1.1%.
- Advantages of REITs: Realty Income achieved a 9% revenue growth in 2025, reaching $5.7 billion, and by maintaining a diverse tenant mix, it mitigates risk, offering a dividend yield of 5.2% and consistently increasing dividends, which boosts investor confidence.
- Stability of Oil Giants: ExxonMobil, known for its 2.9% dividend yield and a beta of just 0.15, indicates low sensitivity to market fluctuations, with a 26% stock price increase over the past year, showcasing its resilience during market downturns, making it an ideal choice for portfolio diversification.
- Risk Management in Portfolios: Amid increasing market volatility, investing in these low-volatility dividend stocks not only reduces investment risk but also provides stable cash flow, making them suitable for risk-averse investors seeking long-term returns.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Market Challenges
- AI Stock Reduction: Citadel Advisors sold 2.9 million shares of Nvidia and 6 million shares of Amazon in Q1, although both remain among its largest holdings, indicating a strategic shift to reallocate capital into more attractive investment opportunities.
- Healthcare Stake Increase: The firm increased its stake in Intuitive Surgical by 30.3% during the first quarter, reflecting confidence in the company's long-term prospects despite facing multiple challenges from competition, lower-margin products, and tariffs.
- Intensifying Market Competition: Intuitive Surgical is encountering increased competition in the robotic-assisted surgery market from Medtronic and Johnson & Johnson; however, the company maintains a significant lead due to its 26 years of market experience and extensive installed base.
- Profitability Outlook: Despite Intuitive Surgical's high valuation with a forward P/E ratio of 39.7, its revenue and earnings growth outpace peers, and its strong competitive edge in the medical device sector justifies this premium.
See More
Citadel Advisors Increases Stake in Intuitive Surgical Amid Challenges
- Increased Stake: Citadel Advisors raised its stake in Intuitive Surgical by 30.3% in Q1, demonstrating confidence in the company's long-term growth potential despite facing challenges such as increased competition and tariffs.
- Market Competition: Intuitive Surgical is encountering competitive pressure in the robotic-assisted surgery market from companies like Medtronic and Johnson & Johnson; however, its 26 years of market experience and strong customer base help maintain its leading position.
- Financial Pressures: Despite relatively strong financial results, Intuitive Surgical's stock has dropped 20% over the past 12 months due to declining product margins and tariff impacts, raising investor concerns about its future performance.
- Long-Term Outlook: Intuitive Surgical is exploring ways to leverage artificial intelligence to enhance its device capabilities, and despite current challenges, its vast market potential and high switching costs provide a solid foundation for future growth.
See More
Three Dividend Stocks Worth Investing In
- Bristol Myers Squibb's Growth Potential: Bristol Myers Squibb's Q1 revenue rose 3% year-over-year to $11.5 billion, with new drug sales increasing 12% to $6.2 billion, indicating a strong recovery in its oncology portfolio that could further enhance sales growth in the future.
- Merck's Product Diversification: Despite competitive pressures, Merck's newer products have an annual revenue exceeding $1 billion, with the pulmonary arterial hypertension drug Winrevair generating $525 million in Q1, an impressive 88% year-over-year increase, showcasing the company's strong performance in new markets.
- Medtronic's Strategic Restructuring: Medtronic announced the spin-off of its diabetes care division into a standalone public company to enhance overall operational efficiency, while its new Pulse Field Ablation devices are positively impacting revenue growth in recent quarters.
- Attractive Dividend Yields: All three companies offer attractive dividend yields, with Bristol Myers at 4.4%, Merck at 3%, and Medtronic at 3.6%, all of which have significantly increased their dividends over the past decade, demonstrating a strong commitment to shareholder returns.
See More
